SCHEMBL212819

SCHEMBL212819

COC(=O)c1nc2ccccc2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.60
KDM4E B2RXH2 5/20 0.60
NPC1 O15118 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
ALDH1A1 P00352 3/20 0.60
MAPT P10636 2/20 0.60
HPGD P15428 2/20 0.60
HSD17B10 Q99714 1/20 0.60
XDH P47989 9/20 0.56
NLRP3 Q96P20 2/20 0.53
GLO1 Q04760 1/20 0.53
TLR4 O00206 1/20 0.53
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
FAAH O00519 2/20 0.50
POLB P06746 1/20 0.49
TP53 P04637 1/20 0.47
CES1 P23141 1/20 0.47
DAGLA Q9Y4D2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28009415 0.83 XDH (0.52) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL28665621 0.82 XDH (0.52) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL3621004 0.82 RAB9A (0.53) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL29868214 0.81 XDH (0.51) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL17951858 0.81 FAAH (0.54) RAB9AKDM4ENPC1ALDH1A1MAPT
SCHEMBL19309799 0.81 KDM4E (0.49) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL5175392 0.80 ALDH1A1 (0.57) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL28676574 0.80 XDH (0.53) RAB9AKDM4EALDH1A1XDHNLRP3
SCHEMBL28667845 0.80 TP53 (0.61) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL11403375 0.79 KDM4E (0.47) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240812-B2 Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2025-03-04 US disclosed
EP-3889134-B1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF KEYTHERA SUZHOU PHARMACEUTICALS CO LTD (CN) 2024-09-25 EP disclosed
CN-113818033-B Electrochemical synthesis method of 2-substituted benzoxazole derivative 诚达药业股份有限公司 2022-10-14 CN disclosed
CN-111989311-B Compound for inhibiting PGE2/EP4 signal transduction, preparation method thereof and application thereof in medicines 凯复(苏州)生物医药有限公司 2022-03-22 CN disclosed
US-20220064113-A1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2022-03-03 US disclosed
CN-110292948-B Application of imines-functionalized imidazole chloride salt as catalyst in preparation of aromatic heterocyclic formate compounds 苏州大学 2022-02-25 CN disclosed
CN-113818033-A Electrochemical synthesis method of 2-substituted benzoxazole derivative 诚达药业股份有限公司 2021-12-21 CN disclosed
EP-3889134-A1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2021-10-06 EP disclosed
CN-111989311-A Compound for inhibiting PGE2/EP4 signal transduction, preparation method thereof and application thereof in medicines 凯复(苏州)生物医药有限公司 2020-11-24 CN disclosed
EP-3737683-A1 INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2020-11-18 EP disclosed
CN-1997649-A Inhibitors of histone deacetylase METHYLGENE INC (CA) 2007-07-11 CN disclosed
EP-1735319-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2006-12-27 EP disclosed
US-20050245518-A1 Antiproliferative agents METHYLGENE, INC. 2005-11-03 US disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
US-5200420-A Inotropic agents for cardiovascular disorders BAYER AKTIENGESELLSCHAFT (DE) 1993-04-06 US disclosed
US-5015473-A Beta-lactamase inhibitors PFIZER INC. (US) 1991-05-14 US disclosed
US-4826833-A ANTIBIOTICS PFIZER INC. (US) 1989-05-02 US disclosed
EP-0039919-A1 Benzoxazole and benzothiazole derivatives with anti-allergic activity USV PHARMACEUTICAL CORPORATION (US) 1981-11-18 EP disclosed
US-4298742-A ANTIALLERGENS USV PHARMACEUTICAL CORPORATION (US) 1981-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064113-A1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF PTGER4, PTGER1, PTGES RAB9A 4488/4885KDM4E 3324/4885NPC1 3159/4885
US-20050245518-A1 Antiproliferative agents HDAC1, HDAC11, HDAC5 RAB9A 3239/4885KDM4E 337/4885NPC1 1178/4885
US-12240812-B2 Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof PTGER4, PTGER1, PTGES RAB9A 4488/4885KDM4E 3324/4885NPC1 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.